Zetagen Therapeutics

Zetagen Therapeutics

Fusologics  (Occupying space in Collaboration Lab 2, 1600/1601), is a pre-clinical orthopedics company developing products that activate a novel and proprietary molecular pathway for growing bone.  Discovered by accident, Fusologics' first product, Nalfuse, addresses a large unmet need for the $4b orthobiologics market and several high volume medical applications for which bone growth leads to optimal outcomes. Based on published pre-clinical data, Nalfuse activates this molecular pathway with a combination of a collagen carrier and an FDA-approved small molecule with over 40 years of high dosage, systemic clinical use for a different indication. As opposed to other products on the market that contain biologic growth factors, such as Medtronic's Infuse (BMP2), which at its peak accounted for ~$900m revenue per year but has since seen a precipitous decline in use due to high cancer risk and significant side effects, Nalfuse has shown the potential to be safer, significantly less costly to manufacture and grow bone just as effectively, if not better.